Needham Maintains Buy on Praxis Precision Medicine, Raises Price Target to $151
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a Buy rating on Praxis Precision Medicine (NASDAQ:PRAX) and raises the price target from $145 to $151.
September 04, 2024 | 9:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating for Praxis Precision Medicine and increased the price target from $145 to $151, indicating a positive outlook for the stock.
The increase in price target from $145 to $151 by Needham suggests a positive outlook for Praxis Precision Medicine, likely boosting investor confidence and potentially leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100